Generics Bulletin Executive Editor Dave Wallace has more than 10 years' experience of reporting on the global generics, biosimilars and value-added medicines industries. Having begun his career in the European chemicals industry, Dave has now spent over a decade with Generics Bulletin, becoming editor from 2018. Bringing his background and education in law to bear on industry litigation as well as national legislative and regulatory affairs, he also keeps a close eye on corporate strategy, personnel moves, and product pipelines. A regular delegate to industry events and conferences, he has a particular interest in local market developments, maintaining close links with national industry representatives. He also organizes and acts as a judge for the annual Global Generics & Biosimilars Award.
Latest From David Wallace
Viatris’ Mylan has received a positive opinion from the EMA’s CHMP for its bevacizumab biosimilar rival to Avastin under two different names. Meanwhile, Accord has received an endorsement for a generic version of Zytiga.
The UK’s Competition and Markets Authority has welcomed a ruling upholding its finding that Lexon broke competition law in relation to nortriptyline, along with a connected £1.2m fine.
Taiwan’s JHL Biotech has rebranded itself as Eden Biologics at the same time as it has announced progress on clinical trials for its denosumab biosimilar candidate.
US off-patent industry association the AAM has announced a fresh board of directors and officers for 2021, reflecting local management changes at multiple leading generics and biosimilars firms.
Aspen expects to report significant growth in its continuing operations for the first half of its financial year, following deals with Sandoz and Viatris that have seen the South African firm divest major businesses in Japan and Europe.
Medicines for Europe has called for fresh efforts to bolster the value added medicines sector and “level the playing field” with the US and its 505(b)(2) pathway, launching a new report setting out the three key areas in which greater EU action is needed.